C of C

ATTN: CERTIFICATE OF CORRECTION BRANCH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OIPE
SEP 24 2007
PATENT & TRADEMARK OFFICE

In Re the Application of:

Wisnewski, Nancy
Brandt, Kevin S.

Patent No.: 7,223,578 B2

Issued: May 29, 2007

Serial No.: 10/679,140

Filed: October 2, 2003

Atty. File No.: AD-1-1

For: "CANINE COX-1 NUCLEIC ACID MOLECULES AND FRAGMENTS THEREOF"

Customer No.: 26949

REQUEST FOR CERTIFICATE OF CORRECTION FOR APPLICANT ERROR 37 CFR § 1.323(a)

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE AND THE DOCUMENTS REFERRED TO AS ENCLOSED HEREIN ARE BEING DEPOSITED WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL, ADDRESSED TO COMMISSIONER FOR PATENTS, ATTN: CERTIFICATE OF CORRECTION BRANCH, P.O. BOX1450, ALEXANDRIA, VA 22313-1450, THIS 21 DAY OF SEPTEMBER 2007.

HESKA CORPORATION

By: Susan Gordon
Susan Gordon

Certificate
SEP 26 2007
of Correction

Commissioner for Patents
ATTN: Certificate of Correction Branch
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

This is a request for a Certificate of Correction under 37 C.F.R. 1.323(a). Attached is Form PTO-1050. The error in claim no. 6 of this patent is due to Applicants' typographic error. Accordingly, Applicants authorize the fee under 37 CFR § 1.20(a) of $100 to be charged to Deposit Account 081930. Please correct the error as follows:

In Column 74, line 6, claim no. 6, remove "nuclei acid" and replace with --nucleic acid--.

Respectfully submitted,

Dated: September 20, 2007

By: Richard J. Stern
Richard J. Stern, Ph.D.
Registration No. 50,668
Heska Corporation
3760 Rocky Mountain Ave.
Loveland, Colorado 80538
Telephone: 970-493-7272, ext. 4174
Facsimile: (970) 619-3011

09/25/2007 EEKUBAY1 00000012 081930 7223578
01 FC:1811 100.00 DA

SEP 26 2007

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : **7,223,578 B2**

DATED : **May 29, 2007**

INVENTOR(S) : **Nancy Wisnewski; Kevin S. Brandt**

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In Column 74, line 6, claim no. 6, remove "nuclei acid" and replace with --nucleic acid--.

MAILING ADDRESS OF SENDER (Please do not use customer number

Heska Corporation
Legal Dept.
3760 Rocky Mountain Ave.
Loveland, CO 80538

PATENT NO. **7,223,578 B2**

No. of additional copies

→

SEP 2 6 2007

AD-1-1

US007223578B2

(12) United States Patent
Wisnewski et al.

(10) **Patent No.:** **US 7,223,578 B2**
(45) **Date of Patent:** **May 29, 2007**

---

(54) **CANINE COX-1 NUCLEIC ACID MOLECULES AND FRAGMENTS THEREOF**

(75) Inventors: **Nancy Wisnewski**, Fort Collins, CO (US); **Kevin S. Brandt**, Fort Collins, CO (US)

(73) Assignee: **Heska Corporation**, Loveland, CO (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 484 days.

(21) Appl. No.: **10/679,140**

(22) Filed: **Oct. 2, 2003**

(65) **Prior Publication Data**

US 2004/0091986 A1 May 13, 2004

Related U.S. Application Data

(62) Division of application No. 09/919,060, filed on Jul. 31, 2001, now Pat. No. 6,638,744.

(60) Provisional application No. 60/224,486, filed on Aug. 11, 2000.

(51) **Int. Cl.**

C12N 9/02	(2006.01)
C12N 1/20	(2006.01)
C12N 15/00	(2006.01)
C12Q 1/00	(2006.01)
C12Q 1/68	(2006.01)
C12Q 21/04	(2006.01)
C07H 21/04	(2006.01)

(52) **U.S. Cl.** **435/189**; 435/4; 435/6; 435/440; 435/69.1; 435/71.1; 435/252.3; 435/320.1; 536/23.2; 536/23.5

(58) **Field of Classification Search** 435/189, 435/440, 69.1, 71.1, 4, 6, 252.3, 320.1; 536/23.2, 536/23.5

See application file for complete search history.

(56) **References Cited**

OTHER PUBLICATIONS

Takahashi et al. Immunoaffinity purification and cDNA cloning of human platelet prostaglandin endoperoxide synthase (cyclooxygenase). Biochem Biophys Res Commun. Jan. 31, 1992;182(2):433-8.*

Branden et al. (introduction to Protein Structure, Garland Publishing Inc., New York, p. 247, 1991).*

Takahashi et al. Sequence Alignment—SEQ ID NO. 9, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15 and SEQ ID NO. 16, pp. 15, 1992.*

Guo et al. Protein tolerance to random amino acid change. Proc Natl Acad Sci U S A. Jun. 22, 2004;101(25):9205-10. Epub Jun. 14, 2004.*

Dubois et al., 1998, *The FASEB Journal*, vol. 12, pp. 1063-1072.

Giuliano et al., 1999, *British Journal of Pharmacology*, vol. 126, pp. 1824-1830.

Golden et al., 1999, *Rheumatic Disease Clinics of North America*, vol. 25, No. 2, pp. 359-378.

Khan et al., 1998, *Toxicologic Pathology*, vol. 26, No. 5, pp. 612-620.

Laufer et al., 1999., *Inflamm. res.*, vol. 48, pp. 133-138.

Masferrer et al., 1994, *Proc. Natl. Acad. Sci. USA*, vol. 91, pp. 3228-3232.

Ricketts et al., 1998, *AJVR*, vol. 59, No. 11, pp. 1441-1446.

Riendeau et al., 1997, *Can. J. Physiol. Pharmacol.* vol. 75, pp. 1088-1095.

Seibert et al., 1994, *Proc. Natl. Acad. Sci. USA*, vol. 91, pp. 12013-12017.

Vane et al., 1998, *Annu. Rev. Pharmacol. Toxicol.*, vol. 38, pp. 97-120.

Vane et al., 1995, *Inflamm Res*, vol. 44, pp. 1-10.

Warner et al., 1999, *Proc. Natl. Acad. Sci. USA*, vol. 96, pp. 7563-7568.

* cited by examiner

Primary Examiner—P. Achutamurthy
Assistant Examiner—Yong D. Pak

(57) **ABSTRACT**

The present invention relates to canine COX-1 and COX-2 proteins; to canine COX-1 and COX-2 nucleic acid molecules, including those that encode such COX-1 and COX-2 proteins, respectively; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes therapeutic compositions comprising such inhibitory compounds, particularly those that specifically inhibit COX-2 activity, as well as the use of such therapeutic compositions to treat animals.

8 Claims, No Drawings

SEP 26 2007

What is claimed is:

1. An isolated nucleic acid molecule, wherein said nucleic acid molecule comprises a nucleic acid sequence selected from the group consisting of:

(a) a nucleic acid sequence that encodes a protein consisting of the amino acid sequence of SEQ ID NO:13; and

(b) a nucleic acid sequence which is complementary over its entire length with the nucleic acid sequence of (a).

2. The isolated nucleic acid molecule of claim **1**, wherein said nucleic acid sequence is selected from the group consisting of SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16.

3. A recombinant virus comprising the isolated nucleic acid molecule set forth in claim **1**.

4. An isolated transformed host cell comprising the isolated nucleic acid molecule set forth in claim **1**.

5. An isolated nucleic acid molecule, wherein said nucleic acid molecule consists of a nucleic acid sequence selected from the group consisting of:

(a) a nucleic acid sequence that is at least 95% identical in sequence to SEQ ID NO:12, or SEQ ID NO:15, wherein said nucleic acid sequence encodes a protein having cyclooxygenase-1 activity; and

(b) a nucleic acid sequence which is complementary over its entire length with the nucleic acid sequence of (a).

✓

6. The isolated nucleic acid molecule of claim **5**, wherein said nucleic acid sequence is selected from the group consisting of:

(a) a nucleic acid sequence encoding a protein having the amino acid sequence of SEQ ID NO:13; and

(b) a nucleic sequence which is complementary over its entire length to the nucleic acid sequence of (a).

7. An isolated nucleic acid molecule consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16.

8. An isolated probe consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO:9 and SEQ ID NO:11.

* * * * *

SEP 26 2007